TXNRD1 and neoplasm: This has also been observed with a novel TRXR-1 inhibitor, PX-916, which was reported show strong anti-tumor activity in a number of animal models but with thrombocytopenia – an approximately 45% reduction in platelet count – noted as a major toxicity [30].